^

World

South Africa suspends AstraZeneca vaccination launch over study

Claire Doyen - Agence France-Presse
South Africa suspends AstraZeneca vaccination launch over study
A health worker prepares an injection of the AstraZeneca/Oxford Covid-19 vaccine on February 7, 2021 at the Mignot Hospital in Le Chesnay near Paris.
AFP / Alain Jocard

JOHANNESBURG, South Africa — South Africa said Sunday it would suspend the start of its COVID-19 vaccinations with the AstraZeneca jab after a study showed the drug failed to prevent mild and moderate cases of the virus variant that has appeared in the country.

Africa's hardest-hit nation was due to start its campaign in the coming days with a million doses of the vaccine developed by AstraZeneca and Oxford.

The suspension marks an important setback for the country, but officials said vaccine deliveries from other producers would soon be available and allow the campaign to move forward. 

"It's a temporary issue that we have to hold on AstraZeneca until we figure out these issues," Health Minister Zweli Mkhize told reporters during a virtual press conference.

The University of Witwatersrand, Johannesburg, which conducted the trial, said in a statement on Sunday that the AstraZeneca vaccine "provides minimal protection against mild-moderate COVID-19 infection" from the South African variant.

But in a full paper due to be published on Monday, AstraZeneca said that none of the 2,000 participants developed serious symptoms.

That could mean it will still have an effect on severe illness, although not enough data is available yet to make a definitive judgment.

Lagging behind in the global vaccination race, South Africa received its first delivery of a million doses on Monday.

An additional 500,000 doses are expected this month.

All are AstraZeneca vaccines produced by the Serum Institute of India, and some 1.2 million health workers were to be first in line for the shots.

"In the next four weeks, we will have the J&J and Pfizer," said Mkhize, referring to vaccines made by Johnson & Johnson and Pfizer/BioNTech.

Discussions with other vaccine producers are also ongoing, particularly Moderna and the makers of the Russian Sputnik V jab.

Mkhize recently announced having reserved 20 million Pfizer/BioNTech doses.

The 1.5 million AstraZeneca vaccines obtained by South Africa, which will expire in April, will be kept until scientists give clear indications on their use, he said.

"The second generation of the vaccine to fight all variants will take longer to produce," said Salim Abdool Karim, epidemiologist and co-chair of the scientific committee at the South African health ministry.

South Africa plans to vaccinate at least 67 percent of its population by the end of the year, or around 40 million people.

The country has recorded nearly 1.5 million infections and more than 46,000 deaths from the virus.

'Protection against deaths'

The AstraZeneca study data, which has not yet undergone peer review, "appear to confirm the theoretical observation that mutations in the virus seen in South Africa will allow ongoing transmission of the virus in vaccinated populations", it said.

"Protection against moderate-severe disease, hospitalisation or death could not be assessed in this study as the target population were at low risk."

But the vaccine developers in Britain said informally that the results offered some hope that the shots could prevent deaths from the variant.

"We may not be reducing the total number of cases but there is still protection against deaths, hospitalisations and severe disease," said Sarah Gilbert, who led the development of the vaccine with the Oxford Vaccine Group.

It could also be "some time" before they determine its effectiveness for older people in fighting the strain, she told BBC television.

AstraZeneca told AFP that "we do believe our vaccine will still protect against severe disease.

"Neutralising antibody activity is equivalent to other COVID-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to 8-12 weeks," added the spokesperson.

Researchers are currently working to update the vaccine, and "have a version with the South African spike sequence in the works" that they would "very much like" to be ready for the autumn, she added.

ASTRAZENECA

COVID-19 VACCINES

NOVEL CORONAVIRUS

SOUTH AFRICA

As It Happens
LATEST UPDATE: May 30, 2023 - 12:56pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

May 30, 2023 - 12:56pm

As negotiations towards a new pandemic treaty pick up pace, observers warn of watered-down efforts to ensure equitable access to the medical products needed to battle future Covid-like threats.

Shaken by the pandemic, the World Health Organization's 194 member states are negotiating an international accord aimed at ensuring countries are better equipped to deal with the next catastrophe, or even prevent it altogether.

The process is still in the early stages, with the aim of reaching an agreement by May 2024.

But critics warn that revisions being made to the preliminary negotiating text are weakening the language -- notably in a key area aimed at preventing the rampant inequity seen in access to vaccines and other medical products during the Covid pandemic.

"I think it is a real step backwards," Suerie Moon, co-director of the Global Health Centre at the Geneva Graduate Institute, told AFP. — AFP

April 20, 2023 - 8:03pm

Africa's first mRNA vaccine hub is ceremonially launched on Thursday to acclaim from the UN's global health chief, who hailed it as a historic shift to help poor countries gain access to life-saving jabs.

The facility was set up in the South African city of Cape Town in 2021 on the back of the success of revolutionary anti-Covid vaccines introduced by Pfizer/BioNTech and Moderna.

"This precious project... will bring a paradigm shift in addressing the serious problem we faced, the equity problem, during the pandemic, so (that) it's not repeated again," World Health Organization (WHO) head Tedros Adhanom Ghebreyesus tells a media briefing to mark the inauguration. — AFP

March 22, 2023 - 3:37pm

China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.

The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for "emergency use" by Beijing's health regulator, the company said in a statement.

It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details. — AFP

March 1, 2023 - 1:53pm

COVID-19 vaccine maker Novavax raises doubts about its ability to continue its business, announcing plans to cut spending after struggles in rolling out its coronavirus jab.

Shares of Novavax plummeted 25 percent in extended trading, after the company reported fourth-quarter earnings that missed analyst estimates.

While the firm should have enough money to fund operations, the situation is "subject to significant uncertainty," it says in a statement. — AFP

February 17, 2023 - 8:53am

The protection against Covid-19 from being previously infected lasts at least as long as that offered by vaccination, one of the largest studies conducted on the subject says.

Ten months after getting Covid, people still had an 88% lower risk of reinfection, hospitalisation and death, according to the study published in the Lancet journal.

That makes this natural immunity "at least as durable, if not more so" than two doses of Pfizer or Moderna's vaccines, the study says.

The authors nevertheless emphasized that their findings should not discourage vaccination, which remains the safest way to get immunity. — AFP

Philstar
  • Latest
  • Trending
Latest
Recommended
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with
-->